Jonathan Gutman
Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cord Blood Stem Cell Transplantation | 20 | 2024 | 103 | 5.780 |
Why?
| | Hematopoietic Stem Cell Transplantation | 24 | 2025 | 675 | 5.510 |
Why?
| | Leukemia, Myeloid, Acute | 26 | 2026 | 682 | 4.740 |
Why?
| | Graft vs Host Disease | 16 | 2025 | 264 | 4.160 |
Why?
| | Transplantation Conditioning | 17 | 2025 | 186 | 3.180 |
Why?
| | Azacitidine | 11 | 2026 | 156 | 2.340 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 13 | 2026 | 279 | 1.950 |
Why?
| | Sulfonamides | 13 | 2026 | 580 | 1.720 |
Why?
| | Hematologic Neoplasms | 6 | 2021 | 161 | 1.200 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.850 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.800 |
Why?
| | Myelodysplastic Syndromes | 5 | 2019 | 147 | 0.790 |
Why?
| | Cytomegalovirus Infections | 3 | 2023 | 206 | 0.770 |
Why?
| | Fetal Blood | 6 | 2022 | 342 | 0.770 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2026 | 1953 | 0.700 |
Why?
| | Recurrence | 10 | 2023 | 1135 | 0.690 |
Why?
| | Transplantation, Homologous | 12 | 2025 | 415 | 0.620 |
Why?
| | Neoplasm, Residual | 5 | 2024 | 139 | 0.620 |
Why?
| | Graft Rejection | 4 | 2025 | 540 | 0.610 |
Why?
| | Leukemia | 5 | 2011 | 245 | 0.610 |
Why?
| | Antineoplastic Agents | 7 | 2026 | 2194 | 0.560 |
Why?
| | Vancomycin | 1 | 2019 | 93 | 0.560 |
Why?
| | Thiotepa | 1 | 2018 | 21 | 0.560 |
Why?
| | Clostridium Infections | 1 | 2019 | 74 | 0.560 |
Why?
| | Pregnancy Complications | 1 | 2023 | 592 | 0.530 |
Why?
| | Retrospective Studies | 17 | 2025 | 17066 | 0.490 |
Why?
| | Humans | 76 | 2026 | 144759 | 0.490 |
Why?
| | Adult | 39 | 2025 | 40449 | 0.460 |
Why?
| | Middle Aged | 37 | 2026 | 35875 | 0.420 |
Why?
| | Stem Cell Transplantation | 4 | 2023 | 191 | 0.410 |
Why?
| | Carbon Monoxide | 1 | 2013 | 82 | 0.380 |
Why?
| | Aged | 27 | 2026 | 25913 | 0.370 |
Why?
| | Blood Banks | 2 | 2012 | 50 | 0.360 |
Why?
| | Organ Transplantation | 2 | 2025 | 247 | 0.360 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2012 | 17 | 0.360 |
Why?
| | Young Adult | 16 | 2025 | 14105 | 0.360 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 38 | 0.340 |
Why?
| | Hematopoietic Stem Cells | 3 | 2015 | 420 | 0.340 |
Why?
| | HLA Antigens | 4 | 2019 | 225 | 0.340 |
Why?
| | Treatment Outcome | 16 | 2026 | 11679 | 0.330 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 172 | 0.330 |
Why?
| | Female | 42 | 2026 | 78271 | 0.330 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2017 | 264 | 0.330 |
Why?
| | Hemoglobins | 1 | 2013 | 384 | 0.320 |
Why?
| | Lymphoma | 2 | 2017 | 232 | 0.320 |
Why?
| | Whole-Body Irradiation | 5 | 2019 | 76 | 0.310 |
Why?
| | Graft vs Leukemia Effect | 1 | 2009 | 12 | 0.310 |
Why?
| | Cesarean Section | 1 | 2011 | 224 | 0.300 |
Why?
| | Male | 42 | 2026 | 72315 | 0.290 |
Why?
| | Isoantibodies | 1 | 2009 | 57 | 0.290 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2008 | 11 | 0.280 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1907 | 0.280 |
Why?
| | Immunotherapy, Adoptive | 2 | 2024 | 337 | 0.280 |
Why?
| | Neoplastic Stem Cells | 3 | 2018 | 412 | 0.280 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2023 | 1137 | 0.270 |
Why?
| | Disease-Free Survival | 4 | 2022 | 769 | 0.260 |
Why?
| | Rhinovirus | 1 | 2007 | 57 | 0.260 |
Why?
| | Picornaviridae Infections | 1 | 2007 | 50 | 0.250 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2013 | 127 | 0.250 |
Why?
| | Vidarabine | 2 | 2018 | 32 | 0.240 |
Why?
| | Altitude Sickness | 4 | 2008 | 141 | 0.230 |
Why?
| | Clonal Evolution | 2 | 2017 | 47 | 0.230 |
Why?
| | Adolescent | 14 | 2025 | 22428 | 0.220 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2020 | 881 | 0.220 |
Why?
| | Histocompatibility Testing | 3 | 2016 | 121 | 0.220 |
Why?
| | Chronic Disease | 3 | 2022 | 1813 | 0.220 |
Why?
| | Prognosis | 7 | 2024 | 4282 | 0.210 |
Why?
| | Mutation | 3 | 2024 | 4089 | 0.200 |
Why?
| | Antigens, CD19 | 1 | 2024 | 129 | 0.200 |
Why?
| | Immune Reconstitution | 1 | 2023 | 9 | 0.200 |
Why?
| | Acetates | 2 | 2023 | 80 | 0.200 |
Why?
| | Altitude | 5 | 2007 | 473 | 0.200 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2009 | 917 | 0.190 |
Why?
| | Living Donors | 1 | 2005 | 280 | 0.190 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 397 | 0.190 |
Why?
| | Unrelated Donors | 3 | 2021 | 38 | 0.190 |
Why?
| | Pulmonary Edema | 3 | 2007 | 106 | 0.190 |
Why?
| | Medical Oncology | 1 | 2025 | 332 | 0.180 |
Why?
| | Carrier Proteins | 2 | 2017 | 737 | 0.180 |
Why?
| | Quinazolines | 2 | 2023 | 266 | 0.180 |
Why?
| | Siblings | 1 | 2022 | 195 | 0.170 |
Why?
| | Nuclear Proteins | 2 | 2017 | 748 | 0.170 |
Why?
| | Chimerism | 1 | 2021 | 35 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2017 | 985 | 0.170 |
Why?
| | Salvage Therapy | 2 | 2019 | 162 | 0.170 |
Why?
| | Myeloablative Agonists | 2 | 2018 | 23 | 0.170 |
Why?
| | Allografts | 1 | 2021 | 150 | 0.160 |
Why?
| | Stem Cells | 2 | 2015 | 626 | 0.160 |
Why?
| | Autoimmune Diseases | 1 | 2024 | 463 | 0.160 |
Why?
| | Sirolimus | 2 | 2019 | 281 | 0.160 |
Why?
| | Antibodies, Monoclonal | 2 | 2017 | 1519 | 0.150 |
Why?
| | Survival Analysis | 3 | 2018 | 1382 | 0.150 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 17 | 0.150 |
Why?
| | Breathing Exercises | 1 | 2019 | 21 | 0.150 |
Why?
| | Relaxation Therapy | 1 | 2019 | 19 | 0.150 |
Why?
| | Leukocytes | 1 | 2021 | 295 | 0.150 |
Why?
| | Antiviral Agents | 3 | 2023 | 767 | 0.150 |
Why?
| | Remission Induction | 4 | 2026 | 307 | 0.150 |
Why?
| | Busulfan | 2 | 2020 | 16 | 0.140 |
Why?
| | Fetus | 1 | 2023 | 803 | 0.140 |
Why?
| | Mountaineering | 3 | 2008 | 36 | 0.140 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 120 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 265 | 0.140 |
Why?
| | Quality of Life | 2 | 2022 | 3185 | 0.140 |
Why?
| | Cyclosporine | 1 | 2019 | 265 | 0.140 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2013 | 293 | 0.140 |
Why?
| | Optic Nerve | 2 | 2008 | 67 | 0.130 |
Why?
| | Socioeconomic Factors | 1 | 2022 | 1326 | 0.130 |
Why?
| | Psychotherapy | 1 | 2019 | 190 | 0.130 |
Why?
| | Intracranial Pressure | 2 | 2008 | 65 | 0.130 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.130 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 7 | 0.130 |
Why?
| | Child | 9 | 2025 | 22633 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 51 | 0.130 |
Why?
| | Risk Factors | 5 | 2025 | 10779 | 0.120 |
Why?
| | Administration, Oral | 1 | 2019 | 847 | 0.120 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 846 | 0.120 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 56 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1982 | 0.120 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 5 | 0.120 |
Why?
| | Myelin Sheath | 2 | 2008 | 168 | 0.120 |
Why?
| | Adipocytes, White | 1 | 2015 | 18 | 0.120 |
Why?
| | Leukocytosis | 1 | 2015 | 32 | 0.120 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 95 | 0.120 |
Why?
| | Gene Frequency | 1 | 2017 | 481 | 0.120 |
Why?
| | Pregnancy | 2 | 2023 | 7190 | 0.110 |
Why?
| | Pulmonary Diffusing Capacity | 2 | 2013 | 78 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2017 | 171 | 0.110 |
Why?
| | Aged, 80 and over | 7 | 2024 | 8265 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 680 | 0.100 |
Why?
| | Incidence | 3 | 2016 | 2879 | 0.100 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 547 | 0.100 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.100 |
Why?
| | Transplantation Chimera | 2 | 2012 | 56 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 442 | 0.100 |
Why?
| | Pyrazoles | 1 | 2017 | 509 | 0.100 |
Why?
| | Antilymphocyte Serum | 1 | 2012 | 61 | 0.100 |
Why?
| | Pyridazines | 1 | 2013 | 57 | 0.090 |
Why?
| | Graft Survival | 2 | 2025 | 526 | 0.090 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 87 | 0.090 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 60 | 0.090 |
Why?
| | Thrombocytopenia | 1 | 2014 | 205 | 0.090 |
Why?
| | Bone Marrow | 3 | 2021 | 304 | 0.090 |
Why?
| | Sequence Deletion | 1 | 2012 | 193 | 0.090 |
Why?
| | Hematopoiesis | 2 | 2010 | 194 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 254 | 0.090 |
Why?
| | Ganciclovir | 1 | 2011 | 53 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 675 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2014 | 291 | 0.090 |
Why?
| | Lung Diseases | 2 | 2011 | 787 | 0.090 |
Why?
| | Neoplasms | 2 | 2019 | 2875 | 0.090 |
Why?
| | Tissue and Organ Procurement | 2 | 2025 | 346 | 0.080 |
Why?
| | Adipose Tissue | 1 | 2015 | 652 | 0.080 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 380 | 0.080 |
Why?
| | Pedigree | 1 | 2012 | 514 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2019 | 1152 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 255 | 0.080 |
Why?
| | Acute Disease | 2 | 2012 | 1030 | 0.080 |
Why?
| | Thrombosis | 1 | 2014 | 393 | 0.080 |
Why?
| | Length of Stay | 1 | 2016 | 1337 | 0.080 |
Why?
| | Leukocyte Count | 2 | 2024 | 316 | 0.080 |
Why?
| | Caregivers | 1 | 2019 | 1049 | 0.080 |
Why?
| | Umbilical Cord | 1 | 2010 | 91 | 0.080 |
Why?
| | Blood Donors | 1 | 2011 | 143 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2016 | 1129 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 573 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1134 | 0.080 |
Why?
| | Treatment Failure | 2 | 2009 | 365 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2024 | 1054 | 0.080 |
Why?
| | Cell Differentiation | 3 | 2015 | 2050 | 0.080 |
Why?
| | Opportunistic Infections | 1 | 2009 | 45 | 0.070 |
Why?
| | Mycosis Fungoides | 1 | 2009 | 62 | 0.070 |
Why?
| | Prednisolone | 1 | 2008 | 66 | 0.070 |
Why?
| | Comorbidity | 1 | 2013 | 1658 | 0.070 |
Why?
| | Infant | 4 | 2014 | 10034 | 0.070 |
Why?
| | Nepal | 4 | 2008 | 32 | 0.070 |
Why?
| | Warfarin | 1 | 2008 | 170 | 0.060 |
Why?
| | Family | 1 | 2012 | 679 | 0.060 |
Why?
| | Child, Preschool | 4 | 2014 | 11787 | 0.060 |
Why?
| | Heparin | 1 | 2008 | 244 | 0.060 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 289 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2014 | 2496 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2007 | 307 | 0.060 |
Why?
| | Time Factors | 3 | 2025 | 7173 | 0.060 |
Why?
| | Intracranial Hypertension | 1 | 2007 | 41 | 0.060 |
Why?
| | Mice, SCID | 2 | 2019 | 369 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2009 | 784 | 0.060 |
Why?
| | Thromboembolism | 1 | 2007 | 125 | 0.060 |
Why?
| | Emergency Treatment | 1 | 2007 | 124 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2019 | 5408 | 0.060 |
Why?
| | Algorithms | 3 | 2009 | 1837 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2009 | 1173 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3671 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 240 | 0.060 |
Why?
| | Mice, Inbred NOD | 2 | 2019 | 610 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2007 | 331 | 0.050 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2007 | 182 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 474 | 0.050 |
Why?
| | Syphilis, Cutaneous | 1 | 2004 | 3 | 0.050 |
Why?
| | Treponema pallidum | 1 | 2004 | 8 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2005 | 290 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 2089 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1985 | 0.050 |
Why?
| | Anxiety Disorders | 1 | 2007 | 373 | 0.050 |
Why?
| | Anticoagulants | 1 | 2008 | 722 | 0.050 |
Why?
| | Cohort Studies | 2 | 2011 | 5960 | 0.050 |
Why?
| | Cytomegalovirus | 1 | 2023 | 168 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2019 | 1325 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 398 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2023 | 180 | 0.040 |
Why?
| | Sialic Acid Binding Ig-like Lectin 3 | 1 | 2021 | 10 | 0.040 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2021 | 17 | 0.040 |
Why?
| | CD56 Antigen | 1 | 2021 | 35 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 668 | 0.040 |
Why?
| | CD3 Complex | 1 | 2021 | 111 | 0.040 |
Why?
| | Phenylurea Compounds | 1 | 2020 | 112 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2730 | 0.040 |
Why?
| | Tarsal Bones | 1 | 1999 | 14 | 0.040 |
Why?
| | Clubfoot | 1 | 1999 | 7 | 0.040 |
Why?
| | Ultrasonography | 3 | 2008 | 770 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 60 | 0.040 |
Why?
| | Calcaneus | 1 | 1999 | 31 | 0.040 |
Why?
| | Benzimidazoles | 1 | 2020 | 190 | 0.040 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 11 | 0.040 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 23 | 0.040 |
Why?
| | Electron Transport Complex II | 1 | 2018 | 28 | 0.040 |
Why?
| | Genes, myc | 1 | 1998 | 50 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 1053 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 969 | 0.040 |
Why?
| | Gene Targeting | 1 | 1998 | 82 | 0.040 |
Why?
| | Succinate Dehydrogenase | 1 | 2018 | 57 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 267 | 0.030 |
Why?
| | Tendons | 1 | 1999 | 129 | 0.030 |
Why?
| | Acetazolamide | 2 | 2008 | 26 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 210 | 0.030 |
Why?
| | NADP | 1 | 2016 | 55 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 478 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 1999 | 243 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 585 | 0.030 |
Why?
| | Sesquiterpenes | 1 | 2016 | 52 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 51 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1047 | 0.030 |
Why?
| | Cell Fusion | 1 | 2015 | 49 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2014 | 4154 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 205 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 323 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 162 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7990 | 0.030 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2014 | 14 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 322 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 406 | 0.030 |
Why?
| | Severity of Illness Index | 3 | 2007 | 2925 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2015 | 320 | 0.030 |
Why?
| | Animals | 5 | 2019 | 38058 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 415 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 375 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 376 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2115 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 851 | 0.020 |
Why?
| | Philadelphia Chromosome | 1 | 2013 | 18 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2014 | 294 | 0.020 |
Why?
| | Pyrimidines | 1 | 2017 | 532 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2014 | 167 | 0.020 |
Why?
| | Survivors | 1 | 2016 | 520 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2018 | 935 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1075 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1490 | 0.020 |
Why?
| | DNA | 1 | 1998 | 1463 | 0.020 |
Why?
| | Probability | 1 | 2012 | 310 | 0.020 |
Why?
| | Mice | 3 | 2019 | 18339 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 375 | 0.020 |
Why?
| | Cryopreservation | 1 | 2012 | 110 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2011 | 172 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 1998 | 1499 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2014 | 405 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1257 | 0.020 |
Why?
| | Hospitalization | 2 | 2014 | 2433 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2182 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2011 | 254 | 0.020 |
Why?
| | Apoptosis | 1 | 2018 | 2430 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 433 | 0.020 |
Why?
| | Viral Load | 1 | 2011 | 526 | 0.020 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2008 | 14 | 0.020 |
Why?
| | Disease Progression | 1 | 2017 | 2847 | 0.020 |
Why?
| | Donor Selection | 1 | 2009 | 79 | 0.020 |
Why?
| | Travel | 1 | 2008 | 136 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2061 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3121 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2007 | 20 | 0.020 |
Why?
| | Gangrene | 1 | 2007 | 11 | 0.020 |
Why?
| | Bed Rest | 1 | 2007 | 15 | 0.020 |
Why?
| | Nifedipine | 1 | 2007 | 27 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2007 | 60 | 0.020 |
Why?
| | Albuterol | 1 | 2007 | 73 | 0.020 |
Why?
| | Iliac Artery | 1 | 2007 | 55 | 0.020 |
Why?
| | Linear Models | 1 | 2008 | 854 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3409 | 0.020 |
Why?
| | Sulfones | 1 | 2007 | 127 | 0.010 |
Why?
| | Purines | 1 | 2007 | 187 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2008 | 724 | 0.010 |
Why?
| | Femoral Artery | 1 | 2007 | 190 | 0.010 |
Why?
| | Reference Values | 1 | 2007 | 797 | 0.010 |
Why?
| | Leg | 1 | 2007 | 239 | 0.010 |
Why?
| | Heart Rate | 1 | 2008 | 855 | 0.010 |
Why?
| | Piperazines | 1 | 2007 | 381 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2004 | 183 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2117 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5992 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 2004 | 171 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1489 | 0.010 |
Why?
| | Disopyramide | 1 | 1981 | 1 | 0.010 |
Why?
| | Heart Block | 1 | 1981 | 40 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1716 | 0.010 |
Why?
| | Israel | 1 | 1999 | 46 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1999 | 166 | 0.010 |
Why?
| | 3T3 Cells | 1 | 1998 | 156 | 0.010 |
Why?
| | HIV Infections | 1 | 2012 | 3154 | 0.010 |
Why?
| | Radiography | 1 | 1999 | 844 | 0.010 |
Why?
| | Pyridines | 1 | 1981 | 605 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 1998 | 383 | 0.010 |
Why?
| | Reoperation | 1 | 1999 | 630 | 0.010 |
Why?
| | Binding Sites | 1 | 1998 | 1329 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2930 | 0.010 |
Why?
| | Bundle-Branch Block | 1 | 1981 | 36 | 0.000 |
Why?
| | Heart Conduction System | 1 | 1981 | 95 | 0.000 |
Why?
|
|
Gutman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|